Product Pipeline

We have multiple and diverse cancer immunotherapies in our pipeline. These are in clinical and preclinical development directed against a range of cancer targets that have been identified and validated by Immatics’ proprietary XPRESIDENT® technology platform.




  • Discovery
  • Lead
  • CMC
  • Phase I/II
Bispecific TCR/BiTE®
Multiple Programs
Bispecific TCR/mAb
Multiple Programs
Bispecific mAb
Multiple Programs
Multiple Programs